DDInter1822 DDInter298
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Tobramycin {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Tobramycin {u} (Compound) resembles {v} (Compound) Gentamicin
Gentamicin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Tobramycin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Carboplatin (Compound)
Tobramycin (Compound) resembles Gentamicin (Compound) and Gentamicin (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)